Vergho Daniel Claudius, Loeser Andreas, Kocot Arkadius, Spahn Martin, Riedmiller Hubertus
Department of Urology, Julius Maximilian University Medical School, Oberduerrbacher Str, 6, D-97080, Würzburg, Germany.
BMC Res Notes. 2012 Jun 1;5:5. doi: 10.1186/1756-0500-5-264.
To evaluate oncological and clinical outcome in patients with renal cell carcinoma (RCC) and tumor thrombus involving inferior vena cava (IVC) treated with nephrectomy and thrombectomy.
We identified 50 patients with a median age of 65 years, who underwent radical surgical treatment for RCC and tumor thrombus of the IVC between 1997 and 2010. The charts were reviewed for pathological and surgical parameters, as well as complications and oncological outcome.
The median follow-up was 26 months. In 21 patients (42%) distant metastases were already present at the time of surgery. All patients underwent radical nephrectomy, thrombectomy and lymph node dissection through a flank (15 patients/30%), thoracoabdominal (14 patients/28%) or midline abdominal approach (21 patients/42%), depending upon surgeon preference and upon the characteristics of tumor and associated thrombus. Extracorporal circulation with cardiopulmonary bypass (CPB) was performed in 10 patients (20%) with supradiaphragmal thrombus of IVC. Cancer-specific survival for the whole cohort at 5 years was 33.1%. Survival for the patients without distant metastasis at 5 years was 50.7%, whereas survival rate in the metastatic group at 5 years was 7.4%. Median survival of patients with metastatic disease was 16.4 months.On multivariate analysis lymph node invasion, distant metastasis and grading were independent prognostic factors. There was no statistically significant influence of level of the tumor thrombus on survival rate. Indeed, patients with supradiaphragmal tumor thrombus (n = 10) even had a better outcome (overall survival at 5 years of 58.33%) than the entire cohort.
An aggressive surgical approach is the most effective therapeutic option in patients with RCC and any level of tumor thrombus and offers a reasonable longterm survival. Due to good clinical and oncological outcome we prefer the use of CPB with extracorporal circulation in patients with supradiaphragmal tumor thrombus. Cytoreductive surgery appears to be beneficial for patients with metastatic disease, especially when consecutive therapy is performed. Although sample size of our study cohort is limited consistent with some other studies lymph node invasion, distant metastasis and grading seem to have prognostic value.
评估接受肾切除术和血栓切除术治疗的肾细胞癌(RCC)合并下腔静脉(IVC)肿瘤血栓患者的肿瘤学和临床结局。
我们确定了50例中位年龄为65岁的患者,他们在1997年至2010年间接受了针对RCC和IVC肿瘤血栓的根治性手术治疗。回顾病历以获取病理和手术参数,以及并发症和肿瘤学结局。
中位随访时间为26个月。21例患者(42%)在手术时已有远处转移。所有患者均根据外科医生的偏好以及肿瘤和相关血栓的特征,通过侧腹(15例患者/30%)、胸腹联合(14例患者/28%)或腹部中线入路(21例患者/42%)接受了根治性肾切除术、血栓切除术和淋巴结清扫术。10例(20%)患有IVC膈上血栓的患者进行了体外循环心肺转流(CPB)。整个队列5年的癌症特异性生存率为33.1%。无远处转移患者5年生存率为50.7%,而转移组5年生存率为7.4%。转移性疾病患者的中位生存期为16.4个月。多因素分析显示,淋巴结侵犯、远处转移和分级是独立的预后因素。肿瘤血栓水平对生存率无统计学显著影响。实际上,患有膈上肿瘤血栓的患者(n = 10)甚至比整个队列有更好的结局(5年总生存率为58.33%)。
积极的手术方法是RCC合并任何水平肿瘤血栓患者最有效的治疗选择,并能提供合理的长期生存。由于良好的临床和肿瘤学结局,我们倾向于对患有膈上肿瘤血栓的患者使用CPB进行体外循环。减瘤手术似乎对转移性疾病患者有益,尤其是在进行连续治疗时。尽管我们研究队列的样本量有限,但与其他一些研究一致,淋巴结侵犯、远处转移和分级似乎具有预后价值。